atomoxetine (Strattera)
ApprovedCompleted 0 watching 0 views this week๐ฅ Hot
85
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 2โ
Phase 35
ApprovedAbout atomoxetine (Strattera)
atomoxetine (Strattera) is a approved stage product being developed by Eli Lilly for ADHD. The current trial status is completed. This product is registered under clinical trial identifier NCT00181948. Target conditions include ADHD.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00181948 | Approved | Completed |
Competing Products
20 competing products in ADHD